Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574597 | 0.87 | NPC1 (0.47) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1574915 | 0.86 | ADAM17 (0.50) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1575367 | 0.85 | CASP3 (0.47) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1574331 | 0.85 | ADAM17 (0.50) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1574722 | 0.81 | ALDH1A1 (0.47) | NPC1RAB9ANAMPT | |
| SCHEMBL1574478 | 0.80 | ADAM17 (0.47) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1575705 | 0.78 | OPRM1 (0.45) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1575747 | 0.77 | OPRM1 (0.43) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL1575457 | 0.75 | NPC1 (0.46) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL5466325 | 0.74 | NPC1 (0.54) | ADAM17NPC1RAB9ASMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | ADAM17 2205/4885NPC1 413/4885RAB9A 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.